Mesoblast (MESO) Change in Accured Expenses (2021 - 2022)

Mesoblast (MESO) posted quarterly Change in Accured Expenses of -$49000.0 for Q1 2022, down 88.46% on a QoQ basis from -$26000.0 in Q4 2021.

Mesoblast (MESO) Change in Accured Expenses (2021 - 2022) Analysis & Trends

Mesoblast (MESO) has reported Change in Accured Expenses for 2 consecutive years, with -$49000.0 the latest figure, recorded in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Accured Expenses (Qtr)
1	Oculis Holding AG	66,831.58 Bn	66,831.30 Bn	-	1.13 Mn
2	Nanobiotix	1,916.61 Bn	1,916.55 Bn	-	-
3	Akari Therapeutics	976.78 Bn	976.78 Bn	-	931,000.00
4	BeOne Medicines	471.48 Bn	466.69 Bn	1.35 Bn	-16.82 Mn
5	Vertex Pharmaceuticals	121.78 Bn	114.53 Bn	2.59 Bn	23.10 Mn
6	Regeneron Pharmaceuticals	69.87 Bn	61.12 Bn	3.31 Bn	107.70 Mn
7	Belite Bio	63.06 Bn	63.06 Bn	-	-
8	Argenx Se	55.78 Bn	50.60 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.54 Bn	34.53 Bn	959.66 Mn	-176.03 Mn
10	Mesoblast	18.90 Bn	18.77 Bn	-	-

Download Data